Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Davide Capodanno
Based on 118 articles published since 2008
(Why 118 articles?)

Between 2008 and 2019, D. Capodanno wrote the following 118 articles about Coronary Artery Disease.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5
1 Guideline A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. 2018

Rossini, Roberta / Tarantini, Giuseppe / Musumeci, Giuseppe / Masiero, Giulia / Barbato, Emanuele / Calabrò, Paolo / Capodanno, Davide / Leonardi, Sergio / Lettino, Maddalena / Limbruno, Ugo / Menozzi, Alberto / Marchese, U O Alfredo / Saia, Francesco / Valgimigli, Marco / Ageno, Walter / Falanga, Anna / Corcione, Antonio / Locatelli, Alessandro / Montorsi, Marco / Piazza, Diego / Stella, Andrea / Bozzani, Antonio / Parolari, Alessandro / Carone, Roberto / Angiolillo, Dominick J / Anonymous911159 / Anonymous921159 / Anonymous931159 / Anonymous941159 / Anonymous951159 / Anonymous961159 / Anonymous971159 / Anonymous981159 / Anonymous991159 / Anonymous1001159 / Anonymous1011159 / Anonymous1021159 / Anonymous1031159 / Anonymous1041159 / Anonymous1051159 / Anonymous1061159 / Anonymous1071159 / Anonymous1081159 / Anonymous1091159 / Anonymous1101159 / Anonymous1111159 / Anonymous1121159 / Anonymous1131159. ·Dipartimento Emergenze e Aree Critiche, Ospedale Santa Croce e Carle, Cuneo, Italy. Electronic address: roberta.rossini2@gmail.com. · Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Dipartimento Emergenze e Aree Critiche, Ospedale Santa Croce e Carle, Cuneo, Italy. · Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy. · Division of Cardiology, Department of Cardio-Thoracic Sciences, Università degli Studi della Campania "Luigi Vanvitelli," Naples, Italy. · Division of Cardiology, Cardio-Thoracic-Vascular Department, Azienda Ospedaliero Universitaria "Policlinico-Vittorio Emanuele, Catania, Italy; Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. · Coronary Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. · Cardiovascular Department, Humanitas Research Hospital, Rozzano, Italy. · U.O.C. Cardiologia, Azienda USL Toscana Sudest, Grosseto, Italy. · Unità Operativa di Cardiologia, Azienda Ospedaliero-Universitaria di Parma, Italy. · U.O.C. Cardiologia Interventistica, Anthea Hospital, GVM Care & Research, Bari, Italy. · Cardiology Unit, Cardio-Thoraco-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. · Swiss Cardiovascular Centre Bern, Bern University Hospital, Bern, Switzerland. · Degenza Breve Internistica e Centro Trombosi ed Emostasi, Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy. · Department of Immunohematology and Transfusion Medicine, Thrombosis and Hemostasis Center, ASST Papa Giovanni XXIII, Bergamo, Italy. · Department of Anaesthesia and Critical Care, AORN Dei Colli, Naples, Italy. · Dipartimento di Chirurgia Generale, Humanitas Research Hospital and University, Milano, Italy. · Policlinico Vittorio Emanuele di Catania, Catania, Italy. · Chirurgia Vascolare, Università di Bologna, Ospedale Sant'Orsola-Malpighi, Bologna, Italy. · UOC Chirurgia Vascolare, Dipartimento di Scienze Chirurgiche, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy. · Dipartimento di Scienze Biomediche per la Salute, Policlinico San Donato IRCCS, University of Milano, Milan, Italy. · Azienda Ospedaliera Universitaria Città della salute e della scienza, Torino, Italy. · Division of Cardiology, University of Florida, College of Medicine-Jacksonville, Jacksonville, Florida. ·JACC Cardiovasc Interv · Pubmed #29519377.

ABSTRACT: Perioperative management of antithrombotic therapy in patients treated with coronary stents undergoing surgery remains poorly defined. Importantly, surgery represents a common reason for premature treatment discontinuation, which is associated with an increased risk in mortality and major adverse cardiac events. However, maintaining antithrombotic therapy to minimize the incidence of perioperative ischemic complications may increase the risk of bleeding complications. Although guidelines provide some recommendations with respect to the perioperative management of antithrombotic therapy, these have been largely developed according to the thrombotic risk of the patient and a definition of the hemorrhagic risk specific to each surgical procedure, key to defining the trade-off between ischemia and bleeding, is not provided. These observations underscore the need for a multidisciplinary collaboration among cardiologists, anesthesiologists, hematologists and surgeons to reach this goal. The present document is an update on practical recommendations for standardizing management of antithrombotic therapy management in patients treated with coronary stents (Surgery After Stenting 2) in various types of surgery according to the predicted individual risk of thrombotic complications against the anticipated risk of surgical bleeding complications. Cardiologists defined the thrombotic risk using a "combined ischemic risk" approach, while surgeons classified surgeries according to their inherent hemorrhagic risk. Finally, a multidisciplinary agreement on the most appropriate antithrombotic treatment regimen in the perioperative phase was reached for each surgical procedure.

2 Guideline Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. 2018

Byrne, Robert A / Stefanini, Giulio G / Capodanno, Davide / Onuma, Yoshinobu / Baumbach, Andreas / Escaned, Javier / Haude, Michael / James, Stefan / Joner, Michael / Jüni, Peter / Kastrati, Adnan / Oktay, Semih / Wijns, William / Serruys, Patrick W / Windecker, Stephan. ·Deutsches Herzzentrum München, Technische Universität München, Germany. ·EuroIntervention · Pubmed #28948934.

ABSTRACT: A previous Task Force of the European Society of Cardiology (ESC) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) provided a report on recommendations for the non-clinical and clinical evaluation of coronary stents. Following dialogue with the European Commission, the Task Force was asked to prepare an additional report on the class of devices known as bioresorbable scaffolds (BRS). Five BRS have CE-mark approval for use in Europe. Only one device -the Absorb bioresorbable vascular scaffold- has published randomized clinical trial data and this data show inferior outcomes to conventional drug-eluting stents (DES) at 2-3 years. For this reason, at present BRS should not be preferred to conventional DES in clinical practice. The Task Force recommends that new BRS devices should undergo systematic non-clinical testing according to standardized criteria prior to evaluation in clinical studies. A clinical evaluation plan should include data from a medium sized, randomized trial against DES powered for a surrogate end point of clinical efficacy. Manufacturers of successful devices receive CE- mark approval for use and must have an approved plan for a large-scale randomized clinical trial with planned long-term follow-up.

3 Editorial Angiographic or Functional Success?: Rethinking the Goal of Percutaneous Coronary Intervention. 2018

Capodanno, Davide. ·Division of Cardiology, Cardio-Thoracic-Vascular Department, Azienda Ospedaliero Universitaria "Policlinico-Vittorio Emanuele," Catania, Italy; and the Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. Electronic address: dcapodanno@gmail.com. ·JACC Cardiovasc Interv · Pubmed #29361448.

ABSTRACT: -- No abstract --

4 Editorial No Benefit of Different Drug or Design on Clinical Outcomes of First-Generation Polymeric Scaffolds: Does Resorption Time Play a Better Role? 2017

Capodanno, Davide. ·Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy. Electronic address: dcapodanno@gmail.com. ·JACC Cardiovasc Interv · Pubmed #28216221.

ABSTRACT: -- No abstract --

5 Editorial Bioresorbable scaffolds for calcified lesions: not a free lunch! 2016

Capodanno, Davide. ·Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy. ·EuroIntervention · Pubmed #26999678.

ABSTRACT: -- No abstract --

6 Editorial Does the SYNTAX score get on your nerves? Practical considerations on how and when avoiding it to maximize its usefulness with no waste of time. 2012

Capodanno, Davide / Tamburino, Corrado. · ·Int J Cardiol · Pubmed #22330001.

ABSTRACT: The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) score is a useful tool to guide decision-making in patients undergoing three-vessel disease and left main percutaneous coronary intervention. However, someone perceives the SYNTAX score as a labor-intensive surrogate with no added utility over clinical judgment and technical experience. We aimed at reviewing the current limitations of the SYNTAX score and provided practical considerations on how and when this angiographic tool should be used with the goal in mind to maximize its usefulness in the catheterization laboratory.

7 Editorial Unraveling the EXCEL: promises and challenges of the next trial of left main percutaneous coronary intervention. 2012

Capodanno, Davide / Tamburino, Corrado. · ·Int J Cardiol · Pubmed #22075415.

ABSTRACT: The Evaluation of Xience Prime or Xience V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial is a multicenter, ongoing trial conducted in patients with left main disease and SYNTAX score ≤ 32 to establish the presumptive advantage of percutaneous coronary intervention (PCI) versus bypass surgery in patients with less complex coronary artery disease than those enrolled in the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial. In this article, we aimed at critically discussing key features and issues relevant to design and clinical interpretation of this new contemporary trial of left main PCI.

8 Editorial Evolution of stents: past, present and future. 2009

Tamburino, Corrado / Capodanno, Davide. · ·Expert Rev Cardiovasc Ther · Pubmed #19419249.

ABSTRACT: -- No abstract --

9 Review Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. 2018

Romano, Sara / Buccheri, Sergio / Mehran, Roxana / Angiolillo, Dominick J / Capodanno, Davide. ·a Division of Cardiology , CAST, P.O. "Rodolico", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", University of Catania , Catania , Italy. · b Cardiovascular Institute, Icahn School of Medicine at Mount Sinai , New York , NY , USA. · c University of Florida, College of Medicine , Jacksonville , FL , USA. ·Expert Opin Drug Saf · Pubmed #30223690.

ABSTRACT: INTRODUCTION: Despite the significant advances in the pharmacological and interventional management of patients with cardiovascular disease (CVD) over the last decades, cardiovascular mortality remains the leading cause of death. Large randomized clinical trials have investigated the efficacy and safety of different antithrombotic medications in patients with CVD. Although female gender is generally underrepresented in these clinical trials, most analyses clearly indicate that both men and women may accrue therapeutic benefits from antithrombotic management strategies. AREAS COVERED: This review aims to provide a comprehensive and focused update on gender-related comparative clinical studies of antithrombotic therapies in patients suffering from CVD. EXPERT OPINION: Current evidence supports the understanding of a similar therapeutic effect between genders with signals of an increased risk of bleeding in women. However, important gaps in evidence exist due to the overall limited percentage of women that have been enrolled in randomized controlled trials. A greater awareness of gender-related issues in antithrombotic therapy should be promoted among physicians and further evidence from large clinical trials looking at the safety and efficacy balance of different antithrombotic strategies in women is warranted.

10 Review State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives. 2017

Gargiulo, Giuseppe / Valgimigli, Marco / Capodanno, Davide / Bittl, John A. ·Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland. ·EuroIntervention · Pubmed #28844033.

ABSTRACT: Evidence from studies published more than 10 years ago suggested that patients receiving first-generation drug-eluting stents (DES) needed dual antiplatelet therapy (DAPT) for at least 12 months. Current evidence from randomised controlled trials (RCT) reported within the past five years suggests that patients with stable ischaemic heart disease who receive newer-generation DES need DAPT for a minimum of three to six months. Patients who undergo stenting for an acute coronary syndrome benefit from DAPT for at least 12 months, but a Bayesian network meta-analysis confirms that extending DAPT beyond 12 months confers a trade-off between reduced ischaemic events and increased bleeding. However, the network meta-analysis finds no credible increase in all-cause mortality if DAPT is lengthened from three to six months to 12 months (posterior median odds ratio [OR] 0.98; 95% Bayesian credible interval [BCI]: 0.73-1.43), from 12 months to 18-48 months (OR 0.87; 95% BCI: 0.64-1.17), or from three to six months to 18-48 months (OR 0.86; 95% BCI: 0.63-1.21). Future investigation should focus on identifying scoring systems that have excellent discrimination and calibration. Although predictive models should be incorporated into systems of care, most decisions about DAPT duration will be based on clinical judgement and patient preference.

11 Review Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta-Analysis. 2017

Kotronias, Rafail A / Kwok, Chun Shing / George, Sudhakar / Capodanno, Davide / Ludman, Peter F / Townend, Jonathan N / Doshi, Sagar N / Khogali, Saib S / Généreux, Philippe / Herrmann, Howard C / Mamas, Mamas A / Bagur, Rodrigo. ·Keele Cardiovascular Research Group, Institute for Applied Clinical Science and Centre for Prognosis Research, Institute of Primary Care and Health Sciences, University of Keele, Stoke-on-Trent, United Kingdom. · Oxford University Clinical Academic Graduate School, Oxford University, Oxford, United Kingdom. · The Heart Centre, Royal Stoke Hospital, University Hospital of North Midlands Trust, Stoke-on-Trent, United Kingdom. · Cardio-Thoracic-Vascular Department, Ferrarotto Hospital University of Catania, Italy. · Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom. · The Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom. · Cardiovascular Research Foundation, New York, NY. · Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY. · Morristown Medical Center, Morristown, NJ. · Cardiology Division, Department of Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA. · Keele Cardiovascular Research Group, Institute for Applied Clinical Science and Centre for Prognosis Research, Institute of Primary Care and Health Sciences, University of Keele, Stoke-on-Trent, United Kingdom rodrigobagur@yahoo.com. · Division of Cardiology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada. · Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. ·J Am Heart Assoc · Pubmed #28655733.

ABSTRACT: BACKGROUND: Recent recommendations suggest that in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation and coexistent significant coronary artery disease, the latter should be treated before the index procedure; however, the evidence basis for such an approach remains limited. We performed a systematic review and meta-analysis to study the clinical outcomes of patients with coronary artery disease who did or did not undergo revascularization prior to transcatheter aortic valve implantation. METHODS AND RESULTS: We conducted a search of Medline and Embase to identify studies evaluating patients who underwent transcatheter aortic valve implantation with or without percutaneous coronary intervention. Random-effects meta-analyses with the inverse variance method were used to estimate the rate and risk of adverse outcomes. Nine studies involving 3858 participants were included in the meta-analysis. Patients who underwent revascularization with percutaneous coronary intervention had a higher rate of major vascular complications (odd ratio [OR]: 1.86; 95% confidence interval [CI], 1.33-2.60; CONCLUSIONS: Our analysis suggests that revascularization before transcatheter aortic valve implantation confers no clinical advantage with respect to several patient-important clinical outcomes and may be associated with an increased risk of major vascular complications and 30-day mortality. In the absence of definitive evidence, careful evaluation of patients on an individual basis is of paramount importance to identify patients who might benefit from elective revascularization.

12 Review Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. 2017

Collet, Carlos / Asano, Taku / Miyazaki, Yosuke / Tenekecioglu, Erhan / Katagiri, Yuki / Sotomi, Yohei / Cavalcante, Rafael / de Winter, Robbert J / Kimura, Takeshi / Gao, Runlin / Puricel, Serban / Cook, Stéphane / Capodanno, Davide / Onuma, Yoshinobu / Serruys, Patrick W. ·Department of Cardiology, Academic Medical Center, Universiteit van Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam-Zuidoost, Netherlands. · Department of Interventional Cardiology, 's-Gravendijkwal 230, 3015 CE Rotterdam, Netherlands. · Department of Cardiovascular Medicine, Kyoto University Hospital, Shogoin Kawaharacho, Sakyo Ward, Kyoto, Kyoto Prefecture 606-8507, Japan. · Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, 10 Beijing, China. · Department of Cardiology, Fribourg University and Hospital, Avenue de l'Europe 20, 1700 Fribourg, Switzerland. · Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Via Salvatore Citelli, 6, 95124 Catania CT, Italy. · Imperial Department of Medicine, Imperial College of London, Kensington, London SW7 2AZ, UK. ·Eur Heart J · Pubmed #28430908.

ABSTRACT: Aims: To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions. Methods and results: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp-Hartung method was used to compute odds ratios (OR) and 95% confidence intervals (CI). The primary safety outcome of interest was the risk of definite/probable device thrombosis (DT). The primary efficacy outcome of interest was the risk of target lesion failure (TLF). Five randomized clinical trials (n = 1730) were included. Patients treated with Absorb BVS had a higher risk of definite/probable DT compared with patients treated with EES (OR 2.93, 95%CI 1.37-6.26, P = 0.01). Very late DT (VLDT) occurred in 13 patients [12/996 (1.4%, 95%CI: 0.08-2.5) Absorb BVS vs. 1/701 (0.5%, 95%CI: 0.2-1.6) EES; OR 3.04; 95%CI 1.2-7.68, P = 0.03], 92% of the VLDT in the BVS group occurred in the absence of dual antiplatelet therapy (DAPT). Patients treated with Absorb BVS had a trend towards higher risk of TLF (OR 1.48, 95%CI 0.90-2.42, P = 0.09), driven by a higher risk of target vessel myocardial infarction and ischaemia-driven target lesion revascularization. No difference was found in the risk of cardiac death. Conclusion: Compared with EES, the use of Absorb BVS was associated with a higher rate of DT and a trend towards higher risk of TLF. VLDT occurred in 1.4% of the patients, the majority of these events occurred in the absence of DAPT.

13 Review Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions. 2017

Capodanno, Davide / Angiolillo, Dominick J. ·Ferrarotto Hospital, University of Catania, Catania, Italy. · University of Florida College of Medicine-Jacksonville, Jacksonville, Florida. Electronic address: dominick.angiolillo@jax.ufl.edu. ·JACC Cardiovasc Interv · Pubmed #28279311.

ABSTRACT: The introduction of bioresorbable vascular scaffolds (BVS) for clinical use has raised a number of questions on whether current dual-antiplatelet therapy (DAPT) recommendations after drug-eluting stent (DES) implantation, mostly deriving from data on second-generation DES, are also applicable to this completely different technology. This article aims to review the technical shortcomings of BVS-the most extensively studied fully bioresorbable coronary stent-and its contemporary rates of scaffold thrombosis, with a focus on recommendations for DAPT duration.

14 Review Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. 2017

Dzeshka, Mikhail S / Brown, Richard A / Capodanno, Davide / Lip, Gregory Y H. ·University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham, West Midlands B18 7QH, UK; Department of Internal Medicine I, Grodno State Medical University, Gorkogo 80, Grodno 230009, Belarus. · University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham, West Midlands B18 7QH, UK. · Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Via Salvatore Citelli 6, CT 95124, Italy. · University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham, West Midlands B18 7QH, UK; Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg Hospital Science and Innovation Center, Søndre Skovvej 15, Aalborg 9100, Denmark. Electronic address: g.y.h.lip@bham.ac.uk. ·Interv Cardiol Clin · Pubmed #27886825.

ABSTRACT: Stroke prevention is the main priority in the management cascade of atrial fibrillation. Most patients require long-term oral anticoagulation (OAC) and may require percutaneous coronary intervention. Prevention of recurrent cardiac ischemia and stent thrombosis necessitate dual antiplatelet therapy (DAPT) for up to 12 months. Triple antithrombotic therapy with OAC plus DAPT of shortest feasible duration is warranted, followed by dual antithrombotic therapy of OAC and antiplatelet agent, and OAC alone after 12 months. Because of elevated risk of hemorrhagic complications, new-generation drug-eluting stents, lower-intensity OAC, radial access, and routine use of gastric protection with proton pump inhibitors are recommended.

15 Review Bioresorbable Scaffolds: Clinical Outcomes and Considerations. 2016

Capodanno, Davide. ·Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, via Citelli 6, Catania 95124, Italy. Electronic address: dcapodanno@gmail.com. ·Interv Cardiol Clin · Pubmed #28582033.

ABSTRACT: Bioresorbable scaffolds (BRS) have been engineered to eliminate the theoretic stimulus to late coronary events, a caveat of conventional metallic drug-eluting stents (DESs). Outcome benefits of BRSs over current-generation DESs are expected to accrue after complete bioresorption. Before this timeframe, BRSs need to prove at least similarly safe and effective compared with DESs. Several randomized studies of the Absorb BRS have been made available. Several manufacturers are at the beginning of their line of clinical development of competing BRSs. This article reviews the contemporary clinical outcomes of the Absorb scaffold, and provides an updated state of the art on the other players in the BRS arena.

16 Review Update on clinical evidence (Part II): A summary of the main post market studies. 2016

Tamburino, Corrado / Capranzano, Piera / Francaviglia, Bruno / Ina Tamburino, Claudia / Longo, Giovanni / Capodanno, Davide. ·Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy. · Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy. pcapranzano@gmail.com. ·Catheter Cardiovasc Interv · Pubmed #27797461.

ABSTRACT: Bioresorbable vascular scaffolds (BVS, Absorb, Abbott Vascular, Santa Clara, CA) received the CE mark in October 2011, and were approved by the Food and Drug Administration in July 2016. After their introduction in clinical practice a broad amount of post-marketing clinical experience with BVS has been generated so far in Europe and outside the United States. The available BVS registries differ in many aspects, including their being single-center or multicenter, single-arm or controlled, sponsored or investigator-initiated, published or presented at a large-scale international meeting. This article provides an overview of clinical results of the main post-marketing studies of BVS available. © 2016 Wiley Periodicals, Inc.

17 Review Bioresorbable vascular scaffold in patients with complex coronary artery disease. 2016

Tamburino, Claudia I / Capranzano, Piera / Longo, Giovanni / Immè, Sebastiano / Tamburino, Giacomo / Scalia, Matteo / Condorelli, Antonio / Francaviglia, Bruno / LA Manna, Alessio / Sgroi, Carmelo / Grasso, Carmelo / DI Salvo, Maria E / Capodanno, Davide / Tamburino, Corrado. ·University of Catania, Ferrarotto Hospital, Catania, Italy - claudiatamburino@live.it. ·Minerva Cardioangiol · Pubmed #27128353.

ABSTRACT: The advent of fully bioresorbable stent technology is heralded as breakthrough technology in the current era of percutaneous coronary interventions (PCI). Bioresorbable scaffolds (BRS) have the potential to introduce a paradigm shift in interventional cardiology, representing an anatomical and functional "vascular restoration" therapy instead of an artificial stiff tube encased by persistent metallic foreign body. Among BRS, the everolimus-eluting scaffold (ABSORB, Abbott Vascular, Santa Clara, CA, USA) has been the most extensively investigated in clinical studies. The use of ABSORB in the treatment of relatively simple lesions appears to provide a similar degree of safety and efficacy compared with metallic drug-eluting stent (DES) treated under randomized trials conditions, but patients treated in real-world practice are far more complex than those included in randomized trials. Therefore, several ABSORB all-comers registries dealing with real world conditions are being performed. Their currently available results are summarized in the present overview.

18 Review Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. 2016

Capodanno, Davide / Angiolillo, Dominick J. ·a Ferrarotto Hospital , University of Catania , Catania , Italy. · b University of Florida College of Medicine-Jacksonville , Jacksonville , FL , USA. ·Expert Rev Cardiovasc Ther · Pubmed #26953527.

ABSTRACT: Pretreatment with oral P2Y12 inhibitors occurs each time clopidogrel, prasugrel, ticagrelor are given to patients with suspected coronary artery disease before definition of the coronary anatomy. In acute coronary syndromes, the practice of administering oral P2Y12 inhibitors upstream has been the object of significant controversy in recent years, following the publication of two trials of pretreatment in non-ST-segment elevation acute coronary syndromes and ST-segment elevation myocardial infarction, respectively. The introduction in the market of cangrelor - the first intravenous P2Y12 inhibitor - represents a new opportunity but also a new challenge for clinicians. This article reviews current recommendations and supporting evidence surrounding pretreatment with oral and intravenous P2Y12 inhibitors in patients with acute coronary syndromes.

19 Review Three-Dimensional Angle Assessment and Plaque Distribution Classification in Left Main Disease: Impact of Geometry on Outcome. 2015

Capodanno, Davide / Gargiulo, Giuseppe / Longo, Giovanni / Tamburino, Corrado. ·Ferrarotto Hospital, University of Catania, Catania, Italy. ·Rev Cardiovasc Med · Pubmed #26198560.

ABSTRACT: Bifurcation geometry and plaque distribution in a diseased left main artery (LM) have the potential to drive operators' decisions regarding treatment strategies, techniques, and material selection. The three-dimensional (3D) geometry of the LM bifurcation typically results in specific patterns of plaque distribution. Plaque distribution may, in turn, significantly affect the procedural and long-term clinical and angiographic outcomes of LM percutaneous coronary intervention. Each LM bifurcation must be treated according to its unique anatomic and pathologic characteristics. Novel classification schemes of plaque distribution and 3D assessment may be valuable aids to obtaining a working picture of the bifurcation geometry.

20 Review The Ultimaster® coronary stent system: state of the art. 2015

Longo, G / La Manna, A / Capodanno, D / Tamburino, C. ·Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy - lamanna.cardio@gmail.com. ·Minerva Cardioangiol · Pubmed #25900560.

ABSTRACT: Percutaneous coronary intervention (PCI) has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stent (BMS) and then first- and second-generation drug-eluting stents (DES) have enhanced the results of PCI by improving early results and reducing the risk of restenosis and stent thrombosis (ST). The delay of re-endothelialization and recovery of endothelial function after stenting as well as inhibition of vascular repair after DES implantation, in part related to permanent polymers, are consider important part of ST pathophysiology mechanism. Several progresses have been made to overcome this issue, among them the development of new more biocompatible - first - and completely biodegradable - then - polymer coatings. A third-generation DES using a biodegradable polymer and eluting sirolimus (Ultimaster®, Terumo Corporation, Tokyo, Japan) has been recently introduced to overcome the long-term adverse vascular reactions. Thanks to the polymer coating applied to the outside surface only (abluminal side), the total drug dose applied on the stent platform has been reduced, leaving the luminal side of the stent free from drug and polymer to enhance endothelial coverage. Indeed, 3-4 months after implantation, the Ultimaster® DES has lost most of its coating, acquiring a profile similar to conventional BMS. This article reviews the recent publications investigating the safety and effectiveness of the bioresorbable polymer sirolimus-eluting Ultimaster® stent (BP-SES), for the treatment of coronary artery lesions.

21 Review Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. 2015

Capodanno, Davide / Angiolillo, Dominick J. ·From the Department of General Surgery and Medical-Surgical Specialties, Ferrarotto Hospital, University of Catania, Catania, Italy (D.C.) · and Division of Cardiology, University of Florida College of Medicine-Jacksonville (D.J.A.). ·Circ Cardiovasc Interv · Pubmed #25717045.

ABSTRACT: -- No abstract --

22 Review A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. 2015

Rossini, Roberta / Oltrona Visconti, Luigi / Musumeci, Giuseppe / Filippi, Alessandro / Pedretti, Roberto / Lettieri, Corrado / Buffoli, Francesca / Campana, Marco / Capodanno, Davide / Castiglioni, Battistina / Cattaneo, Maria Grazia / Colombo, Paola / De Luca, Leonardo / De Servi, Stefano / Ferlini, Marco / Limbruno, Ugo / Nassiacos, Daniele / Piccaluga, Emanuela / Raisaro, Arturo / Ravizza, PierFranco / Senni, Michele / Tabaglio, Erminio / Tarantini, Giuseppe / Trabattoni, Daniela / Zadra, Alessandro / Riccio, Carmine / Bedogni, Francesco / Febo, Oreste / Brignoli, Ovidio / Ceravolo, Roberto / Sardella, Gennaro / Bongo, Sante / Faggiano, Pompilio / Cricelli, Claudio / Greco, Cesare / Gulizia, Michele Massimo / Berti, Sergio / Bovenzi, Francesco / Anonymous3470811 / Anonymous3480811 / Anonymous3490811 / Anonymous3500811. ·Dipartimento Cardiovascolare, AO Papa Giovanni XXIII, Bergamo, Italia. ·Catheter Cardiovasc Interv · Pubmed #25380511.

ABSTRACT: The number of percutaneous coronary interventions (PCI) is increasing worldwide. Follow-up strategies after PCI are extremely heterogeneous and can greatly affect the cost of medical care. Of note, clinical evaluations and non-invasive exams are often performed to low risk patients. In the present consensus document, practical advises are provided with respect to a tailored follow-up strategy on the basis of patients' risk profile. Three strategies follow-up have been defined and types and timing of clinical and instrumental evaluations are reported. Clinical and interventional cardiologists, cardiac rehabilitators, and general practitioners, who are in charge to manage post-PCI patients, equally contributed to the creation of the present document.

23 Review Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. 2014

Gargiulo, Giuseppe / Capodanno, Davide / Longo, Giovanni / Capranzano, Piera / Tamburino, Corrado. ·Division of Cardiology, Ferrarotto Hospital, University of Catania, Via Citelli 6, 95124 Catania, Italy. ·Expert Rev Cardiovasc Ther · Pubmed #25220474.

ABSTRACT: NSAIDs are used worldwide by more than 30 million people everyday, given their anti-inflammatory, analgesic and antipyretic effects. NSAIDs are approved for several common adult diseases, including acute and chronic musculoskeletal or inflammatory disease, osteoarthritis, rheumatoid arthritis and other arthritic conditions, as well as for children with juvenile idiopathic arthritis. Importantly, the population commonly taking NSAIDs is that of older individuals who also represent the population with the highest risk for cardiovascular (CV) and gastrointestinal adverse effects. In recent years, a growing body of evidence regarding potential risks from chronic use of NSAIDs has emerged. The aim of this review is to update the available data concerning chronic use of NSAIDs in patients with and without CV disease by analyzing the mechanisms of action, the interference of specific NSAIDs with the established CV protective role of low-dose aspirin, and the potential increased risk of myocardial infarction, stroke, hypertension, heart failure and atrial fibrillation.

24 Review Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. 2014

Giacoppo, Daniele / Capodanno, Davide / Capranzano, Piera / Aruta, Patrizia / Tamburino, Corrado. ·Institute of Cardiology, Cardiothoracovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy. · Institute of Cardiology, Cardiothoracovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy; Excellence Through Newest Advances Foundation, Catania, Italy. Electronic address: dcapodanno@gmail.com. · Institute of Cardiology, Cardiothoracovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy; Excellence Through Newest Advances Foundation, Catania, Italy. ·Am J Cardiol · Pubmed #25001154.

ABSTRACT: Preprocedural statin administration may reduce contrast-induced acute kidney injury (CI-AKI), but current evidence is controversial. Randomized controlled trials (RCTs) comparing preprocedural statin administration before coronary catheterization with standard strategies were searched in MEDLINE/PubMed, EMBASE, Scopus, Cochrane Library, Web of Science, and ScienceDirect databases. The outcome of interest was the incidence of postprocedural CI-AKI. Prespecified subgroup analyses were performed according to baseline glomerular filtration rate (GFR), statin type, and N-acetylcysteine use. Eight RCTs were included for a total of 4,984 patients. The incidence of CI-AKI was 3.91% in the statin group (n = 2,480) and 6.98% in the control group (n = 2,504). In the pooled analysis using a random-effects model, patients receiving statins had 46% lower relative risk (RR) of CI-AKI compared with the control group (RR 0.54, 95% confidence interval [CI] 0.38 to 0.78, p = 0.001). A moderate degree of non-significant heterogeneity was present (I(2) = 41.9%, chi-square = 12.500, p = 0.099, τ² = 0.100). In the subanalysis based on GFR, the pooled RR indicated a persistent benefit with statins in patients with GFR <60 ml/min (RR 0.67, 95% CI 0.45 to 1.00, p = 0.050) and a highly significant benefit in patients with GFR ≥60 ml/min (RR 0.40, 95% CI 0.27 to 0.61, p <0.0001). Statin type and N-acetylcysteine or hydration did not significantly influence the results. In conclusion, preprocedural statin use leads to a significant reduction in the pooled RR of CI-AKI.

25 Review Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. 2013

Capodanno, Davide / Angiolillo, Dominick J. ·Ferrarotto Hospital, University of Catania, Catania, Italy (D.C.) · and University of Florida College of Medicine-Jacksonville, Jacksonville, FL (D.C., D.J.A.). ·Circulation · Pubmed #24366588.

ABSTRACT: -- No abstract --